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Revise Guidelines, or Do We Need
a Randomized Controlled Trial?*
Linda Gillam, MD, MPH
Morristown, New Jersey
The natural history of chronic aortic regurgitation (AR) is
characterized by a series of left ventricular (LV) compensa-
tory mechanisms. Initially, the regurgitant volume is accom-
modated by increases in LV end-diastolic volume and
compliance and associated LV hypertrophy. However, the
concomitant increased wall stress results in increased after-
load and, with it, more hypertrophy. Thus, chronic AR
imposes both a volume and an often underappreciated
pressure load on the left ventricle (1). The natural history of
the condition typically includes a long plateau phase during
which LV ejection performance is maintained and patients
remain asymptomatic, and it is theoretically appealing that
medical intervention at this point might improve outcomes,
notably the need for aortic valve replacement (AVR) and the
development of heart failure.
See page 2084
Candidate pharmacologic agents have included calcium-
channel blockers, notably nifedipine, as well as beta-
blockers and drugs that target the renin-angiotensin system.
Much of what we know about the impact of angiotensin-
converting enzyme (ACE) inhibitors and angiotensin re-
ceptor blockers (ARBs) in the setting of severe AR is
derived from rat studies reported by the group at Laval,
Quebec, Canada. In 2003, Plante et al. (2) reported that
ACE activity and fibronectin expression were increased in
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by high-dose but not low-dose captopril therapy. Subse-
quently, using the same model of chronic severe AR, this
group reported the up-regulation of genes encoding for
procollagen types I and III, fibronectin, atrial natriuretic
peptide, transforming growth factor–beta (2), and connec-
tive tissue growth factor. Treatment with metoprolol and
captopril variably reduced this up-regulation (3). In 2009,
Plante et al. (4) compared the impact of 3 vasodilators—
nifedipine, captopril, and losartan—in male rats with AR.
Although nifedipine-treated animals were similar to con-
trols with regard to hemodynamic parameters, LV dilation,
hypertrophy, and loss of systolic function, captopril or
losartan slowed the onset of these abnormalities (4). How-
ever, when, in a similar model, AR was accompanied by
systemic hypertension, captopril was much less effective (5).
Despite these promising studies, there are limited and
conflicting data concerning the results of renin-angiotensin
system blockade in humans. Lin et al. (6) reported that a
dose of 20 mg twice daily of enalapril favorably influenced
LV remodeling at 1 year in patients with mild to severe AR,
while Banaszewski et al. (7) reported favorable acute and
long-term (12 to 53 months) effects of captopril in patients
with moderate and severe AR, although the study included
no control group. However, the prospective randomized
controlled trial of Evangelista et al. (8) in patients with
chronic severe AR showed no effect of either enalapril (20
mg/day) or nifedipine in time to AVR or echocardiographi-
cally assessed AR volume and LV function. Similarly, a
small retrospective analysis of 18 pediatric patients failed to
show a benefit of ACE inhibitor therapy (9).
In this issue of the Journal, Elder et al. (10) report the
results of a retrospective longitudinal cohort study of pa-
tients with echocardiographic diagnoses of moderate or
severe AR, comparing those who did versus those who did
not receive ACE inhibitors or ARBs.
Their study takes advantage of their ability to use the
echocardiographic records from a single hospital to identify
patients with moderate or severe AR and to combine this
information with regional medical databases that include
pharmacy as well as morbidity and mortality (cardiovascular
and all-cause) outcomes. The goal was to test the hypothesis
that ACE inhibitor or ARB use improves outcomes in
patients with moderate to severe AR.
There is limited information in this report concerning
concomitant cardiac and noncardiac disease, and there are no
apparent exclusions for those with mixed valvular disease.
Although there were high death and overall event rates, only
62 patients underwent AVR, precluding a meaningful analysis
limited to this outcome. Similarly, the investigators are unable
to provide information concerning worsening severity of AR.
Thus, the analysis focuses on differences in all-cause mortality,
cardiovascular, and AR events (heart failure hospitalizations,
heart failure deaths, or AVR) between patients treated with
and without ACE inhibitors or ARBs.
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of their databases to provide an analysis of more than 2,000
patients, by far the largest clinical study evaluating medical
outcomes in patients with AR. Additionally, acknowledging
the differences between groups exposed or not exposed to ACE
inhibitors or ARBs with regard to a number of important
baseline demographic, echocardiographic, and clinical charac-
teristics, they used propensity matching and time dependency
analysis to try to tease out whether the observed differences
represent a cause-effect relationship or spurious findings. They
also performed subgroup analysis between those with and
without LV systolic dysfunction and those with and without
LV dilation.
The major finding was reduced all-cause mortality and
cardiovascular and AR events in the group treated with
ACE inhibitors or ARBs. However, is this strong enough
ammunition for revising guidelines or generating support
for a randomized controlled clinical trial?
Potential Biases and Unappreciated Confounding
Mixed valve disease and echocardiographic grading. All
retrospective cohort studies are limited by methodologic
issues and potential sources of bias that even sophisticated
statistical analyses cannot completely overcome. In this
study, one concern relates to the apparent failure to define
the study cohort as patients with pure AR. Because aortic
valve disease is frequently a mixed process, it is possible that
the benefit of ACE inhibitors or ARBs was predominantly
in those with concomitant aortic stenosis (AS). To this
point, the same group has just published data from a similar
analysis of the databases used for this study, with a focus
instead on AS. They reported an association between ACE
inhibitor or ARB therapy and more favorable outcomes in
patients with AS (11). This begs the question of whether
the apparent impact of ACE inhibitor or ARB therapy in
this study of AR could in fact be due to its effect on AS, or,
conversely, was the “beneficial” effect in patients with AS
actually attributable to concomitant AR? The presence of
unrecognized mitral disease is a related and unaddressed
potential confounding variable. If, as might be anticipated,
this group goes on to assess treatment-associated outcomes
in groups with other forms of valvular disease, it is hoped
that the study groups will be limited to those with a single
type of valve dysfunction.
In this study, another concern is the validity of the
echocardiographic grading of AR and the possibility of
information bias in the diagnosis of patients with moderate
or severe regurgitation. The echocardiographic community
has recognized the challenges of accurate and reproducible
assessment of the severity of valve regurgitation and has
published guidelines that include the use of quantitative
measures (vena contracta, effective regurgitant orifice, re-
gurgitant volume, and regurgitant fraction) (12) in addition
to the measures of jet dimensions, descending aortic flow,
and pressure half-time that were used in this study. Regur-gitant volume and effective regurgitant orifice area have
been reported to supersede traditional AR grading in
predicting overall survival and survival free of AVR under
medical management as well as cardiac events, including
cardiac death, congestive heart failure, and new episodes of
atrial fibrillation (13). Thus, the message of this study would
have been stronger had a more integrated approach to AR
grading been used and had the investigators presented
intraobserver and interobserver variability analyses on a
subset of patients from the echocardiographic database,
including those with mild AR. This would help allay the
concern that, in the context of the overall study findings,
there might have been a tendency to upgrade the severity of
regurgitation in the cohort of patients receiving ACE
inhibitor or ARB therapy, particularly those with larger left
ventricles and/or those receiving diuretic agents. Perhaps
the cohort of patients not receiving ACE inhibitors or
ARBs actually included patients with more severe regurgi-
tation than was appreciated.
What about the adrenergic system? As previously noted,
the Laval group has reported that both beta-blockers and
ACE inhibitors had favorable effects on gene up-regulation
in a rat model of AR (3). Additionally, in 2004, Plante et al.
(14) reported that metoprolol favorably influenced LV
remodeling and systolic dysfunction in rats with chronic
severe AR and that, at 1 year, metoprolol improved survival,
minimized LV hypertrophy, improved LV filling pressures,
decreased LV subendocardial fibrosis, and helped restore
the beta-adrenergic receptors (15). This leads one to con-
sider the potential for the results of this study to be
confounded by concomitant beta-blockade. Indeed, even in
the propensity-matched analysis, the group receiving ACE
inhibitor or ARB therapy included patients with signifi-
cantly greater use of beta-blockers, begging the question of
whether beta-blockers and not ACE inhibitors or ARBs
were the true source of the apparent benefit. Interestingly,
calcium-channel blockers, aspirin, nitrates, statins, diuretic
agents, and digoxin were also used more frequently in the
ACE inhibitor or ARB group, even in the propensity-
matched analysis. Although the investigators argue that
these may be markers of symptomatic heart failure in the
ACE inhibitor or ARB group (i.e., making them “sicker”
and at greater risk), it is equally possible that any or all of
these agents may have been the basis for the improved
outcomes in the ACE inhibitor or ARB group.
Nonvalvular heart disease. It is difficult to ignore the
impulse to play detective in identifying other forms of heart
disease that were differentially present in the groups with
versus without ACE inhibitor or ARB therapy, and one that
immediately comes to mind is coronary disease, the pres-
ence of which would explain the increased prevalence of
aspirin, beta-blockers, nitrates, and calcium-channel block-
ers. Is it possible that the primary benefit of ACE inhibitors
or ARBs was in those with coronary disease? Speculation
along these lines could be endless.
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selected for analysis. In this study, relatively few patients
(n  62) underwent AVR, and thus, the major emphasis of
the report is on improved heart failure–related outcomes.
Although heart failure is a recognized outcome of chronic
severe AR, it is, at best, a nonspecific one, and the small
number of AVRs given the overall prevalence of moderate
and severe AR leads one to ask for more information
concerning both surgical referral practices in the medical
community studied as well as the link between AR and
heart failure as perceived clinically. In other words, it is hard
to reconcile the small number of AVRs with the relatively
large number of heart failure–related events, because AVR
carries a Class I indication for patients with severe AR with
symptoms and/or LV systolic dysfunction (16).
Enough ammunition to revise guidelines, or do we need
a randomized controlled trial? The current American
College of Cardiology and American Heart Association
guidelines for the treatment of patients with AR suggest
that vasodilators be reserved for patients who are symptom-
atic and/or have LV dysfunction and who are not candidates
for AVR (Class I) and as a short-term therapy in patients
who will undergo AVR (Class IIA), leaving as a Class IIB
indication their use in asymptomatic patients with normal
LV systolic function but LV dilation (16). The results of
this study are insufficient to justify an alteration of these
recommendations.
However, perhaps they do justify support for a multi-
center randomized controlled trial with a sample size and
study design robust enough to provide a definitive answer to
the question of whether pharmacologic therapy can influ-
ence the natural history of severe AR. In the most recent
American College of Cardiology and American Heart
Association guidelines for the management of patients with
valvular heart disease, there is only one indication supported
by Level of Evidence: A (data derived from multiple
randomized clinical trials) and a disturbingly large number
supported only by the consensus opinion of experts, case
studies, or standard-of-care (Level of Evidence: C) (16).
Given the prevalence and clinical importance of valvular
heart disease, surely we can commit to studies that will
provide a robust evidence base for therapy.
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